Market Overview

UPDATE: Goldman Sachs Initiates Zoetis at Neutral; Upside Limited From Current Valuation

Share:
Related ZTS
Earnings Scheduled For November 2, 2017
Earnings Scheduled For August 8, 2017
Tracking George Soros's Portfolio - Q3 2017 Update (Seeking Alpha)

Goldman Sachs initiated coverage on Zoetis (NYSE: ZTS) with an Overweight rating and a $33.00 price target.

Goldman Sachs analyst Jami Rubin noted, "ZTS is the largest and only independently traded animal health company, with revenues of over $4.0 bn. We anticipate powerful macro trends in livestock and companion animals to provide tailwinds for sustained top line growth in the 5-7% range, with margin expansion yielding earnings growth in the upper teens through 2014, and low double-digit/high single-digit EPS growth thereafter. As a pure play animal health business, ZTS represents a scarce asset within our healthcare universe; however, as the stock currently trades at 23.5x 2013E we see limited upside from here."

Zoetis closed at $33.82 on Tuesday.

Latest Ratings for ZTS

DateFirmActionFromTo
Nov 2017BMO CapitalMaintainsMarket Perform
Nov 2017Morgan StanleyMaintainsEqual-Weight
Jul 2017Deutsche BankDowngradesBuyHold

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Analyst Ratings

 

Related Articles (ZTS)

View Comments and Join the Discussion!

Partner Center